After a brief delay earlier this year, and following its world-first approval in the UK over the summer, Bayer has now secured FDA approval for its novel therapy, expanding the limited range of nonhormonal options available for managing common menopausal symptoms. The FDA has approved Bayer’s dual neurokinin (NK) inhibitor, elinzanetant, which will be marketed in the US as Lynkuet, for the treatment of moderate to severe vasomotor symptoms (VMS) such as hot flashes and night sweats associated with menopause.
Elinzanetant (BAY-3427080) is a first-in-class, oral, nonhormonal therapy that blocks both neurokinin-1 and neurokinin-3 receptors to modulate a cluster of est...
